[ad_1]
Based on the document “Draft Landscape of COVID-19 Candidates” developed by the World Health Organization (WHO), at the time of writing there are 201 candidate vaccines being tested against SARS-CoV-2 coronavirus. Most of them (156) are in the so-called preclinical experimentation, that is, they are tested in animal models and test tube cells, while the remaining 45 have already been tested inman. Some of the latter are in full phase 3, which, prior approval by the competent authorities, precedes marketing. There are very good hopes for him Oxford vaccine and others preparationsBut it is also drawing a lot of interest from some of those “behind” on the roadmap. One of them, for example, was able to produce neutralizing antibodies in ball in concentrations 10 times higher than those found in patients recovered from COVID-19, the infection caused by the pathogen.
To fine tune the ultra-potent experimental vaccine was an international research team led by scientists from the University of Washington, who collaborated closely with colleagues from the University of North Carolina at Chapel Hill, the Washington National Primate Research Center in Seattle, the Babraham Research Campus in Seattle Cambridge of the Department of Infectious Diseases at Imperial College London and other institutes. The scientists, coordinated by physicians in biochemistry Alexandra Walls and Brooke Fiala, developed the vaccine based on self-assembling nanoparticles built with computational technology from UW Medicine. Simply put, the vaccine was designed to computer. These protein nanoparticles display up to 60 copies of the glycoprotein receptor-binding domain (RBD), a crucial part of the protein S OR Spike that SARS-CoV-2 uses to bind to the ACE2 receptor on human cells, break down the cell wall, pour viral RNA into it, and initiate the replication process, which in turn triggers infection. It is a crucial point to keep in mind if you want to prevent the coronavirus from attacking cells and thus infecting them.
The molecular structure of the nanoparticle-based vaccine candidate is very similar to that of a virus, also for this reason when it is injected it triggers a antibody response extremely powerful. Tested in mice, as indicated, it produced a response 10 times greater than that seen in people infected with the coronavirus. The result is also obtained with dose preferably low. If that is not enough, preparation also generates a strong response from cell B, who play a valuable role in the “immune memory“Basically, just in case it turns out safe and effective, the vaccine could provide strong and long-lasting protection against the SARS-CoV-2 coronavirus. Just what it takes to break the pandemic That brought the whole world to its knees
“We hope that our nanoparticle platform can help fight this pandemic that is causing so much damage to our world,” said Professor Neil King, who invented the technology to design computational vaccines at the Institute for Protein Design at UW Medicine. “The potency, stability and manufacturability of this candidate vaccine sets it apart from many others in development,” added the scientist. Details of the research “Obtaining potent neutralizing antibody responses by protein nanoparticle vaccines designed for SARS-CoV-2” are published in the journal Cell.
[ad_2]
